retatrutide triple agonist obesity glp-1 gip glucagon phase 2 trial First-in-Class 'Triple-G'! Eli Lilly's retatrutide shows promising

Evidence for increased risk of prediabetes in the uremic patient

Long-term body composition changes still depend heavily on: Calorie balance Consistent exercise Nutrition quality Sleep and recovery habits Sustainable lifestyle practices When combined with structured training and appropriate nutrition, L-Carnitine may support overall fitness and body composition goals

Enhance focus, memory, and cognitive performance

This dual action makes tirzepatide a particularly exciting candidate for weight management

Another 2025 survey published in JAMA Health Forum noted that, should Medicare pay for the drugs, it could avoid spending a hypothetical $18.2 billion on obesity-related health expenditures over 10 years while dishing out $65.9 billion annually on the GLP-1s by year 10, thereby negating any savings